Summary

Does understanding the genotype/phenotype of hypertrophic cardiomyopathy (HCM) influence management of the disease in relation to treatment, risk, and counseling? This article discusses the potential clinical value of molecular diagnosis in HCM. The most important contribution of mutation analysis is clarification of diagnosis rather than preclinical diagnosis (testing of asymptomatic carriers).